Bleximenib Breakthrough in High-Risk AML? | Hartmut Döhner, MD

Bleximenib Breakthrough in High-Risk AML? | Hartmut Döhner, MD

TKI + Inotuzumab: Could This Be a Better Treatment? | Anand Patel, MD

TKI + Inotuzumab: Could This Be a Better Treatment? | Anand Patel, MD

Improved Survival with Liso-cel in Relapsed Lymphoma | Manali Kamdar, MD

Promising Early Results: Allogeneic CAR-T for Relapsed Lymphoma! | Supriya Gupta, MD

Venetoclax + Inotuzumab: Changing the Game in Relapsed ALLL | Marlise Luskin, MD

Venetoclax + Inotuzumab: Changing the Game in Relapsed ALLL | Marlise Luskin, MD

Financial Strain & Delayed Treatment in Blood Cancers | Christopher Su, MD

Financial Strain & Delayed Treatment in Blood Cancers | Christopher Su, MD

High-Risk DLBCL: GOLCA Boosts Remission Rates | Marc Hoffmann, MD

High-Risk DLBCL: GOLCA Boosts Remission Rates | Marc Hoffmann, MD

Chemo-Free Option for Frail Lymphoma Patients | Umberto Vitolo, MD

Chemo-Free Option for Frail Lymphoma Patients | Umberto Vitolo, MD

Can MRD Guide Better CLL Treatment With Sonrotoclax? | Marc Hoffmann, MD

Can MRD Guide Better CLL Treatment With Sonrotoclax? | Marc Hoffmann, MD

Less Invasive AML & MDS Monitoring: Blood Tests & Machine Learning | Lisa Pleyer, MD

Less Invasive AML & MDS Monitoring: Blood Tests & Machine Learning | Lisa Pleyer, MD

Less Invasive AML & MDS Monitoring: Blood Tests & Machine Learning | Lisa Pleyer, MD

Less Invasive AML & MDS Monitoring: Blood Tests & Machine Learning | Lisa Pleyer, MD

Real‑World Results for Menin Inhibitors in Hard‑to‑Treat AML | Kuo-Kai Chin, MD